Once again, Baird analyst Colin Sebastian is singing Amazon’s (AMZN) praises.Extra emphasis on the again here. The coronavirus has wreaked havoc on all aspects of daily life but what it has also inadvertently done, is provide Amazon with a monster.
(Bloomberg) -- Kelcy Warren, the billionaire pipeline mogul, has said he’s proud of the Dakota Access oil project like it were his son.So when a judge delivered a surprise ruling this week ordering the pipeline to shut until further environmental.
(Bloomberg) -- Two days after a judge ordered the controversial Dakota Access oil pipeline to shut by early August, its owner Energy Transfer LP is continuing to schedule shipments and has made no moves to take it offline.The Dallas-based company.
Nokia, battling with China's Huawei and Sweden's Ericsson, is trying to strengthen its 5G slate and looking especially to deployment by U.S. telecom companies for growth. Overnight, JP Morgan downgraded Nokia to "neutral" from "overweight", citing a potential loss of.
(Bloomberg) -- The White House wants Congress to pass another stimulus package by the first week in August, before lawmakers head home for their annual summer recess, and to keep the cost at $1 trillion or less, according to Vice.
It hasn’t all been smooth sailing for social media company Pinterest (PINS) since going public last spring. The company exited 2019 with shares below the $19 IPO price after failing to initially meet Wall Street’s expectations. Since May, however, the.
Shares in biopharma Bellus Health (BLU) cratered 72% in Monday’s trading, after the company announced disappointing topline results from its Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough.The Phase 2 RELIEF trial of BLU-5937 did not.
Out on the Street, it’s full speed ahead. Despite the chaotic events of 2020, the S&P 500, which is coming off of its best quarter in more than 20 years, is down by only 2% year-to-date. Somewhat remarkably, the market.
Corvus Pharmaceuticals Inc. (CRVS) shares shot up 115% on Tuesday after the clinical-stage biopharma company said that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.The stock surged to $5.85 in early.
If you are looking for the best ideas for your portfolio you may want to consider some of Mott Capital's top stock picks. Mott Capital, an investment management firm, is bullish on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock. In its Q4.